Multiple Value-creating Catalysts Across the Annexon Portfolio Throughout 2024Pivotal Phase 3 Data for ANX005 in Guillain-Barré Syndrome (GBS) ...

WALTHAM, Mass., May 07, 2024 (GLOBE NEWSWIRE) -- Apellis Pharmaceuticals , Inc. (Nasdaq: APLS), today announced its first quarter 2024 financial results and business highlights.

which were partially offset by a $15.0 million one-time expense in the first quarter related to the discontinuation of systemic pegcetacoplan for cold agglutinin disease (CAD). Selling, General and ...

Cold agglutinin disease is under clinical development by NovelMed Therapeutics and currently in Phase I for Acquired (Autoimmune) Hemolytic Anemia. According to GlobalData, Phase I drugs for Acquired ...

Transfusion of these patients can exacerbate cold agglutinin-mediated haemolysis. Moreover, the workup for these reactions represents a diagnostic challenge due in part to false negative direct ...

In the DECADE trial, the cold agglutinin titer alongside the intensity of coated C3d RBCs in a wide temperature range remained (12). (3) EBV and CMV trigger AIHA, which, in turn, activates the ...

cold agglutinin disease and unspecified antibody-related neurological diseases. It is administered through intravenous and subcutaneous route. The drug candidate is an engineered B-cell modulator. It ...

Peter C. Nowell; Phytohemagglutinin: An Initiator of Mitosis in Cultures of Normal Human Leukocytes *. Cancer Res 1 May 1960; 20 (4): 462–466. Possible factors responsible for the initiation of ...

Share on Facebook. Opens in a new tab or window Share on X. Opens in a new tab or window Share on LinkedIn. Opens in a new tab or window Investigational therapies may soon change the treatment ...